Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$23.40 USD
+0.14 (0.60%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $23.39 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Viridian Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 477 | 425 | 197 | 128 | 27 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 7 | 3 | 2 | 3 |
Total Current Assets | 486 | 431 | 200 | 130 | 30 |
Net Property & Equipment | 2 | 1 | 0 | 0 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 0 |
Total Assets | 490 | 435 | 204 | 131 | 30 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 4 |
Accounts Payable | 2 | 14 | 2 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 24 | 19 | 11 | 10 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 27 | 33 | 14 | 11 | 10 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 20 | 5 | 0 | 0 | 4 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 2 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 48 | 40 | 16 | 11 | 15 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 207 | 142 | 134 | 181 | 0 |
Common Stock (Par) | 1 | 0 | 0 | 0 | 0 |
Capital Surplus | 961 | 741 | 412 | 218 | 184 |
Retained Earnings | -726 | -488 | -358 | -279 | -168 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 442 | 395 | 188 | 120 | 16 |
Total Liabilities & Shareholder's Equity | 490 | 435 | 204 | 131 | 30 |
Total Common Equity | 236 | 253 | 54 | -61 | 16 |
Shares Outstanding | 52.50 | 41.30 | 21.70 | 3.90 | 2.30 |
Book Value Per Share | 4.49 | 6.12 | 2.48 | -15.58 | 6.85 |
Fiscal Year End for Viridian Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 571 | 613 | 477 | 313 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 10 | 14 | 9 | 11 |
Total Current Assets | NA | 582 | 627 | 486 | 324 |
Net Property & Equipment | NA | 2 | 2 | 2 | 2 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 586 | 630 | 490 | 329 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 3 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 3 | 2 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 30 | 23 | 24 | 19 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 37 | 26 | 27 | 23 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 1 | 1 | 1 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 17 | 20 | 20 | 20 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 56 | 48 | 48 | 45 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 200 | 200 | 207 | 135 |
Common Stock (Par) | NA | 1 | 1 | 1 | 0 |
Capital Surplus | NA | 1,169 | 1,157 | 961 | 807 |
Retained Earnings | NA | -839 | -774 | -726 | -659 |
Other Equity | NA | -1 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 529 | 583 | 442 | 284 |
Total Liabilities & Shareholder's Equity | NA | 586 | 630 | 490 | 329 |
Total Common Equity | 0 | 330 | 383 | 236 | 149 |
Shares Outstanding | 63.80 | 63.80 | 63.80 | 52.50 | 43.60 |
Book Value Per Share | 0.00 | 5.17 | 6.00 | 4.49 | 3.41 |